Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 490183, 12 pages
http://dx.doi.org/10.1155/2015/490183
Review Article

Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers

1Emergency Department, Clinical Hospital Centre Rijeka, Krešimirova 42, 51000 Rijeka, Croatia
2Department of Gastroenterology, Clinical Hospital Centre Rijeka, Krešimirova 42, 51000 Rijeka, Croatia
3Department of Psychology, Faculty of Humanities and Social Sciences, University of Rijeka, Sveučilišna Avenija 4, 510000 Rijeka, Croatia
4Department of Gastroenterology and Hepatology, University Clinical Centre Tuzla, Trnovac bb, 76000 Tuzla, Bosnia and Herzegovina

Received 16 March 2015; Accepted 26 May 2015

Academic Editor: Eiji Sakai

Copyright © 2015 Ivana Plavšić et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. J. Brandt, W. D. Chey, A. E. Foxx-Orenstein et al., “An evidence-based position statement on the management of irritable bowel syndrome,” The American Journal of Gastroenterology, vol. 104, supplement 1, pp. S1–S35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. National Collaborating Centre for Nursing and Supportive Care, Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care, 2008.
  3. M. El-Salhy, “Irritable bowel syndrome: diagnosis and pathogenesis,” World Journal of Gastroenterology, vol. 18, no. 37, pp. 5151–5163, 2012. View at Google Scholar · View at Scopus
  4. E. M. M. Quigley and G. Clarke, “A serologic test for irritable bowel syndrome: real meat or bare bones?” Gastroenterology, vol. 137, no. 6, pp. 2168–2170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. El-Salhy, D. Gundersen, J. G. Hatlebakk, and T. Hausken, “Chromogranin A cell density as a diagnostic marker for lymphocytic colitis,” Digestive Diseases and Sciences, vol. 57, no. 12, pp. 3154–3159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. A. Saito, G. M. Petersen, G. R. Locke III, and N. J. Talley, “The genetics of irritable bowel syndrome,” Clinical Gastroenterology and Hepatology, vol. 3, no. 11, pp. 1057–1065, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. Z.-F. Zhang, Z.-J. Duan, L.-X. Wang, D. Yang, G. Zhao, and L. Zhang, “The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies,” BMC Gastroenterology, vol. 14, no. 1, article 23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. J. Lee and K. S. Park, “Irritable bowel syndrome: emerging paradigm in pathophysiology,” World Journal of Gastroenterology, vol. 20, no. 10, pp. 2456–2469, 2014. View at Google Scholar · View at Scopus
  9. L. Chang, M. Adeyemo, I. Karagiannidis et al., “Serum and colonic mucosal immune markers in irritable bowel syndrome,” The American Journal of Gastroenterology, vol. 107, no. 2, pp. 262–272, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Patel, P. Bercik, D. G. Morgan et al., “Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating,” Alimentary Pharmacology & Therapeutics, vol. 41, no. 5, pp. 449–458, 2015. View at Publisher · View at Google Scholar
  11. C. Cremon, L. Gargano, A. M. Morselli-Labate et al., “Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms,” American Journal of Gastroenterology, vol. 104, no. 2, pp. 392–400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Barbara, V. Stanghellini, R. de Giorgio, and R. Corinaldesi, “Functional gastrointestinal disorders and mast cells: implications for therapy,” Neurogastroenterology & Motility, vol. 18, no. 1, pp. 6–17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. H. Park, P. L. Rhee, H. S. Kim et al., “Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome,” Journal of Gastroenterology and Hepatology, vol. 21, no. 1, pp. 71–78, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Öhman, S. Isaksson, A. Lundgren, M. Simrén, and H. Sjövall, “A controlled study of colonic immune activity and β7+ blood T lymphocytes in patients with irritable bowel syndrome,” Clinical Gastroenterology and Hepatology, vol. 3, no. 10, pp. 980–986, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. T. G. Dinan, E. M. M. Quigley, S. M. M. Ahmed et al., “Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?” Gastroenterology, vol. 130, no. 2, pp. 304–311, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Guilarte, J. Santos, I. de Torres et al., “Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum,” Gut, vol. 56, no. 2, pp. 203–209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. G. T. Stewart, “Post-dysenteric colitis,” British Medical Journal, vol. 1, no. 4650, pp. 405–409, 1950. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Schwille-Kiuntke, P. Enck, C. Zendler et al., “Postinfectious irritable bowel syndrome: Follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter,” Neurogastroenterology and Motility, vol. 23, no. 11, pp. e479–e488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Swan, N. P. Duroudier, E. Campbell et al., “Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα,” Gut, vol. 62, no. 7, pp. 985–994, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Ringel and I. M. Carroll, “Alterations in the intestinal microbiota and functional bowel symptoms,” Gastrointestinal Endoscopy Clinics of North America, vol. 19, no. 1, pp. 141–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. El-Salhy, D. Gundersen, J. G. Hatlebakk, and T. Hausken, “Low-grade inflammation in the rectum of patients with sporadic irritable bowel syndrome,” Molecular Medicine Reports, vol. 7, no. 4, pp. 1081–1085, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. L. H. Wang, X. C. Fang, and G. Z. Pan, “Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis,” Gut, vol. 53, no. 8, pp. 1096–1101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Thabane, D. T. Kottachchi, and J. K. Marshall, “Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome,” Alimentary Pharmacology & Therapeutics, vol. 26, no. 4, pp. 535–544, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. E. G. Zoetendal, M. Rajilić-Stojanović, and W. M. De Vos, “High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota,” Gut, vol. 57, no. 11, pp. 1605–1615, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. I. M. Carroll, Y.-H. Chang, J. Park, R. B. Sartor, and Y. Ringel, “Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome,” Gut Pathogens, vol. 2, no. 1, article 19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. P. J. Kennedy, J. F. Cryan, T. G. Dinan, and G. Clarke, “Irritable bowel syndrome: a microbiome-gut-brain axis disorder?” World Journal of Gastroenterology, vol. 20, no. 39, pp. 14105–14125, 2014. View at Publisher · View at Google Scholar
  27. E. Malinen, L. Krogius-Kurikka, A. Lyra et al., “Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome,” World Journal of Gastroenterology, vol. 16, no. 36, pp. 4532–4540, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Clarke, J. F. Cryan, T. G. Dinan, and E. M. Quigley, “Review article: probiotics for the treatment of irritable bowel syndrome—focus on lactic acid bacteria,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 4, pp. 403–413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. A. Villarreal, F. J. Aberger, R. Benrud, and J. D. Gundrum, “Use of broad-spectrum antibiotics and the development of irritable bowel syndrome,” Wisconsin Medical Journal, vol. 111, no. 1, pp. 17–20, 2012. View at Google Scholar · View at Scopus
  30. R. Spiller and C. Lam, “An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome,” Journal of Neurogastroenterology and Motility, vol. 18, no. 3, pp. 258–268, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. S. M. Collins and P. Bercik, “The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease,” Gastroenterology, vol. 136, no. 6, pp. 2003–2014, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Fichna and M. A. Storr, “Brain-gut interactions in IBS,” Frontiers in Pharmacology, vol. 3, article 127, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Öhman and M. Simrén, “New insights into the pathogenesis and pathophysiology of irritable bowel syndrome,” Digestive and Liver Disease, vol. 39, no. 3, pp. 201–215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. W. I. Khan and J. E. Ghia, “Gut hormones: rmerging role in immune activation and inflammation,” Clinical and Experimental Immunology, vol. 161, no. 1, pp. 19–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Cetin, M. Kuhn, H. Kulaksiz et al., “Enterochromaffin cells of the digestive system: cellular source of guanylin, a guanylate cyclase-activating peptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 2935–2939, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. M. El-Salhy, Å. Danielsson, R. Stenling, and L. Grimelius, “Colonic endocrine cells in inflammatory bowel disease,” Journal of Internal Medicine, vol. 242, no. 5, pp. 413–419, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. M. D. Coates, C. R. Mahoney, D. R. Linden et al., “Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome,” Gastroenterology, vol. 126, no. 7, pp. 1657–1664, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Simrén, J. Axelsson, R. Gillberg, H. Abrahamsson, J. Svedlund, and E. S. Björnsson, “Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors,” The American Journal of Gastroenterology, vol. 97, no. 2, pp. 389–396, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Öhman, M. Stridsberg, S. Isaksson, P. Jerlstad, and M. Simrén, “Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms?” The American Journal of Gastroenterology, vol. 107, no. 3, pp. 440–447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Eriksson and K. Oberg, “Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors,” Acta Oncologica, vol. 30, no. 4, pp. 477–483, 1991. View at Publisher · View at Google Scholar · View at Scopus
  41. Biomarkers Definitions Working Group, “Biomarkers and surrogate endpoints: preferred definitions and conceptual framework,” Clinical Pharmacology & Therapeutics, vol. 69, no. 3, pp. 89–95, 2001. View at Publisher · View at Google Scholar
  42. T. J. Connor and B. E. Leonard, “Biological markers of depression,” in Antidepressants: Past, Present and Future, S. Preskorn, J. Feighner, C. Stanga, and R. Ross, Eds., vol. 157, pp. 117–148, Springer, Berlin, Germany, 2004. View at Google Scholar
  43. G. Clarke, E. M. M. Quigley, J. F. Cryan, and T. G. Dinan, “Irritable bowel syndrome: towards biomarker identification,” Trends in Molecular Medicine, vol. 15, no. 10, pp. 478–489, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Bennike, S. Birkelund, A. Stensballe, and V. Andersen, “Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies,” World Journal of Gastroenterology, vol. 20, no. 12, pp. 3231–3244, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Hod, R. Dickman, A. Sperber et al., “Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome,” Neurogastroenterology and Motility, vol. 23, no. 12, pp. 1105–1110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Hauser, M. Tkalcic, S. Pletikosic, N. Grabar, and D. Stimac, “Erythrocyte sedimentation rate—possible role in determining the existence of the low grade inflammation in Irritable Bowel Syndrome patients,” Medical Hypotheses, vol. 78, no. 6, pp. 818–820, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. D. K. Chitkara, M. A. L. van Tilburg, N. Blois-Martin, and W. E. Whitehead, “Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review,” American Journal of Gastroenterology, vol. 103, no. 3, pp. 765–774, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. E. B. Blanchard, J. M. Lackner, J. Jaccard et al., “The role of stress in symptom exacerbation among IBS patients,” Journal of Psychosomatic Research, vol. 64, no. 2, pp. 119–128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. P. J. Kennedy, J. F. Cryan, E. M. Quigley, T. G. Dinan, and G. Clarke, “A sustained hypothalamic-pituitary-adrenal axis response to acute psychosocial stress in irritable bowel syndrome,” Psychological Medicine, vol. 44, no. 14, pp. 3123–3134, 2014. View at Publisher · View at Google Scholar
  50. L. Z. FitzGerald, P. Kehoe, and K. Sinha, “Hypothalamic-pituitary-adrenal axis dysregulation in women with irritable bowel syndrome in response to acute physical stress,” Western Journal of Nursing Research, vol. 31, no. 7, pp. 818–836, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. A. J. Lembo, B. Neri, J. Tolley, D. Barken, S. Carroll, and H. Pan, “Use of serum biomarkers in a diagnostic test for irritable bowel syndrome,” Alimentary Pharmacology and Therapeutics, vol. 29, no. 8, pp. 834–842, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. D. Zhang, P. Shooshtarizadeh, B.-J. Laventie et al., “Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2,” PLoS ONE, vol. 4, no. 2, Article ID e4501, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Sidhu, M. E. McAlindon, J. S. Leeds, J. Skilling, and D. S. Sanders, “The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome,” Journal of Gastrointestinal and Liver Diseases, vol. 18, no. 1, pp. 23–26, 2009. View at Google Scholar · View at Scopus
  54. S. P. Dunlop, D. Jenkins, K. R. Neal, and R. C. Spiller, “Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS,” Gastroenterology, vol. 125, no. 6, pp. 1651–1659, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Sidhu, K. Drew, M. E. McAlindon, A. J. Lobo, and D. S. Sanders, “Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): a shared model for pathogenesis?” Inflammatory Bowel Diseases, vol. 16, no. 3, p. 361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. M. El-Salhy, B. Lomholt-Beck, and T. Hausken, “Chromogranin a as a possible tool in the diagnosis of irritable bowel syndrome,” Scandinavian Journal of Gastroenterology, vol. 45, no. 12, pp. 1435–1439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Camilleri, “Editorial: fecal granins in IBS: cause or indicator of intestinal or colonic irritation?” The American Journal of Gastroenterology, vol. 107, no. 3, pp. 448–450, 2012. View at Publisher · View at Google Scholar
  58. A. G. Roseth, M. K. Fagerhol, E. Aadland, and H. Schjonsby, “Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study,” Scandinavian Journal of Gastroenterology, vol. 27, no. 9, pp. 793–798, 1992. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Dhaliwal, Z. Zeino, C. Tomkins et al., “Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?” Frontline Gastroenterology, vol. 6, no. 1, pp. 14–19, 2014. View at Publisher · View at Google Scholar
  60. J. Keohane, C. O'Mahony, L. O'Mahony, S. O'Mahony, E. M. Quigley, and F. Shanahan, “Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?” The American Journal of Gastroenterology, vol. 105, no. 8, pp. 1788–1795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. A. Tibble, G. Sigthorsson, R. Foster, I. Forgacs, and I. Bjarnason, “Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease,” Gastroenterology, vol. 123, no. 2, pp. 450–460, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Waugh, E. Cummins, P. Royle et al., “Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation,” Health Technology Assessment, vol. 17, no. 55, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. M.-H. Chang, J.-W. Chou, S.-M. Chen et al., “Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome,” Molecular Medicine Reports, vol. 10, no. 1, pp. 522–526, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Tkalcic, S. Pletikosic, and G. Hausr, “Biological and psychological determinants of health related quality of life in irritable bowel syndrome patients,” Journal of Psychosomatic Research, vol. 76, no. 6, p. 516, 2014. View at Publisher · View at Google Scholar
  65. J. Langhorst, A. Junge, A. Rueffer et al., “Elevated human β-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome,” The American Journal of Gastroenterology, vol. 104, no. 2, pp. 404–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Ding, B. Lu, D. Chen, L. Meng, Y. Shen, and S. Chen, “Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome,” Proteomics, vol. 10, no. 14, pp. 2620–2630, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Voss, Y. A. Goo, K. Cain et al., “Searching for the noninvasive biomarker holy grail: are urine proteomics the answer?” Biological Research for Nursing, vol. 13, no. 3, pp. 235–242, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. M. P. Jones, W. D. Chey, S. Singh et al., “A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads,” Alimentary Pharmacology and Therapeutics, vol. 39, no. 4, pp. 426–437, 2014. View at Publisher · View at Google Scholar · View at Scopus